Skip to main content

Table 1 Treatments with biological drugs currently being approved for severe asthma with their target, age of registration, effects and relevant reference studies

From: Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?

 DrugTargetAge of registrationEffectsReferences
 omalizumabanti-IgE mAb≥ 6 years (EMA)
≥ 6 years (FDA)
↓ asthma exacerbations
↓ asthma hospitalizations
↑ asthma control
↓ oral corticosteroids
↑ quality of life
[16] [17] [18]
[19] [20] [21]
[22] [23] [24]
 mepolizumabanti-IL-5 mAb≥ 12 years (EMA)
≥ 6 years (FDA)
↓ asthma exacerbations
↑ asthma control
↓ systemic corticosteroids
↑ pulmonary function
[33] [34] [35]
[36] [37] [38]
 reslizumabanti-IL-5 mAb≥ 18 years (EMA)
≥ 18 years (FDA)
↓ asthma exacerbations
↑ asthma control
↑ pulmonary function
↑ quality of life
[41] [42] [43]
[44]
 benralizumabanti-IL-5Rα
mAb
≥ 18 years (EMA)
≥ 12 years (FDA)
↓ asthma exacerbations
↑ asthma control
↓ oral corticosteroids
[45] [46] [47]
[48] [49] [50]
 dupilumabanti-IL-4Rα
mAb
≥ 12 years (EMA)
≥ 12 years (FDA)
↓ asthma exacerbations
↑ pulmonary function
[51] [52] [53]
[54] [55]
  1. EMA = European Medicines Agency; FDA = Food and Drug Administration; IgE = immunoglobulin E; IL-4Rα = interleukin-4 receptor alfa; IL-5 = interleukin-5; IL-5Rα = interleukin-5 receptor alfa; mAb = monoclonal antibody
\